NASDAQ:MXCT MaxCyte Q3 2026 Earnings Date & Estimates $1.30 +0.05 (+4.00%) Closing price 04:00 PM EasternExtended Trading$1.27 -0.03 (-2.31%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. MaxCyte is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 10, 2026Conference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from MaxCyte in Q3 2026MaxCyte is expected to post earnings of -$0.08 per share on revenue of $7.02 million. In the same quarter a year earlier MaxCyte reported -$0.12 per share on revenue of $6.41 million. MaxCyte last reported on August 12, 2026, posting -$0.08 per share and beating the -$0.09 consensus estimate. MaxCyte has beaten the consensus EPS estimate in 5 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.08Expected Revenue$7.02 millionPrior-Year EPS-$0.12Prior-Year Revenue$6.41 millionExpected Revenue Growth+9.5%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.08 (Beat by +$0.01)Last Quarter Revenue$6.50 millionEPS Beat Rate5 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report MaxCyte Q3 2026 Earnings FAQ When does MaxCyte report Q3 2026 earnings? MaxCyte (NASDAQ:MXCT) is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is MaxCyte's Q3 2026 earnings call? MaxCyte's Q3 2026 earnings conference call is scheduled for Tuesday, November 10, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for MaxCyte? Analysts expect MaxCyte to post earnings of -$0.08 per share for Q3 2026. How much revenue is MaxCyte expected to report? The consensus revenue estimate for MaxCyte is $7.02 million for Q3 2026. MaxCyte Earnings HeadlinesMaxCyte Sees Preliminary Q3 Core Revenue Of About $8.1 Mln, Raises FY26 Guidance; Shares UpOctober 14 at 11:12 PM | rttnews.comMaxCyte stock rallies on initial Q3 revenue, higher FY26 outlookOctober 14 at 11:12 PM | msn.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.October 15 at 1:00 AM | InvestorPlace (Ad)MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue GuidanceOctober 14 at 8:05 AM | globenewswire.comMaxCyte (NASDAQ:MXCT) Shares Down 1% - Time to Sell?October 11, 2026 | americanbankingnews.comMaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development OfficerSeptember 23, 2026 | globenewswire.comSee More MaxCyte Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MaxCyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MaxCyte and other key companies, straight to your email. Email Address About MaxCyteMaxCyte (NASDAQ:MXCT) is a biotechnology company that develops and commercializes cell-engineering technologies for use in biopharmaceutical research, development and manufacturing. Its platform is designed to introduce nucleic acids and other molecules into cells, supporting applications such as cell therapy, gene editing, induced pluripotent stem cells and protein production. The company’s primary offering is the ExPERT platform, which combines electroporation instruments, proprietary processing protocols, software and single-use processing assemblies. MaxCyte provides systems for research and clinical applications, as well as larger-scale manufacturing through products such as its STX, GTx and VLX instruments. Its technologies are used by biotechnology and pharmaceutical companies developing cell-based medicines and other biologic products. Founded in 1998 and headquartered in Rockville, Maryland, MaxCyte serves customers and partners in North America, Europe and other international markets. The company also works with biopharmaceutical developers through technology partnerships and commercial arrangements. Maher Masoud serves as president and chief executive officer.View MaxCyte ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
